KR100951108B1 - 라세믹 또는 광학적으로 활성이 있는 α-글리세로포스포릴콜린 및 그 유도체의 제조방법 - Google Patents
라세믹 또는 광학적으로 활성이 있는 α-글리세로포스포릴콜린 및 그 유도체의 제조방법 Download PDFInfo
- Publication number
- KR100951108B1 KR100951108B1 KR1020080034490A KR20080034490A KR100951108B1 KR 100951108 B1 KR100951108 B1 KR 100951108B1 KR 1020080034490 A KR1020080034490 A KR 1020080034490A KR 20080034490 A KR20080034490 A KR 20080034490A KR 100951108 B1 KR100951108 B1 KR 100951108B1
- Authority
- KR
- South Korea
- Prior art keywords
- racemic
- reaction
- derivatives
- optically active
- choline
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 32
- 239000008777 Glycerylphosphorylcholine Substances 0.000 title description 8
- 229960004956 glycerylphosphorylcholine Drugs 0.000 title description 8
- 238000006243 chemical reaction Methods 0.000 claims abstract description 71
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 claims abstract description 50
- 239000007864 aqueous solution Substances 0.000 claims abstract description 20
- 229950004354 phosphorylcholine Drugs 0.000 claims abstract description 19
- 238000007142 ring opening reaction Methods 0.000 claims abstract description 16
- CTKINSOISVBQLD-GSVOUGTGSA-N (R)-Glycidol Chemical compound OC[C@@H]1CO1 CTKINSOISVBQLD-GSVOUGTGSA-N 0.000 claims abstract description 14
- 239000002841 Lewis acid Substances 0.000 claims abstract description 13
- 150000007517 lewis acids Chemical class 0.000 claims abstract description 13
- CTKINSOISVBQLD-VKHMYHEASA-N (S)-Glycidol Chemical compound OC[C@H]1CO1 CTKINSOISVBQLD-VKHMYHEASA-N 0.000 claims abstract description 10
- 230000000694 effects Effects 0.000 claims abstract description 10
- 230000003287 optical effect Effects 0.000 claims abstract description 7
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- 229960001231 choline Drugs 0.000 claims description 12
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 12
- 150000007529 inorganic bases Chemical class 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 229960004788 choline alfoscerate Drugs 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 5
- 125000001736 nosyl group Chemical group S(=O)(=O)(C1=CC=C([N+](=O)[O-])C=C1)* 0.000 claims description 5
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 5
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 229910052799 carbon Chemical group 0.000 claims description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 claims description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- 239000003495 polar organic solvent Substances 0.000 claims 1
- 239000007858 starting material Substances 0.000 abstract description 13
- 230000003412 degenerative effect Effects 0.000 abstract description 6
- 230000007547 defect Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 208000011580 syndromic disease Diseases 0.000 abstract description 3
- 230000002490 cerebral effect Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 239000012153 distilled water Substances 0.000 description 16
- 239000003456 ion exchange resin Substances 0.000 description 12
- 229920003303 ion-exchange polymer Polymers 0.000 description 12
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 238000000746 purification Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 238000005580 one pot reaction Methods 0.000 description 6
- -1 acyl phospholipid Chemical class 0.000 description 5
- 235000019743 Choline chloride Nutrition 0.000 description 4
- 238000005947 deacylation reaction Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- JZNWSCPGTDBMEW-RXMQYKEDSA-N 2-ammonioethyl (2R)-2,3-dihydroxypropyl phosphate zwitterion Chemical compound NCCOP(O)(=O)OC[C@H](O)CO JZNWSCPGTDBMEW-RXMQYKEDSA-N 0.000 description 2
- VTDOEFXTVHCAAM-UHFFFAOYSA-N 4-methylpent-3-ene-1,2,3-triol Chemical compound CC(C)=C(O)C(O)CO VTDOEFXTVHCAAM-UHFFFAOYSA-N 0.000 description 2
- RNVYQYLELCKWAN-UHFFFAOYSA-N CC1(C)OC(CO)CO1 Chemical compound CC1(C)OC(CO)CO1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 2
- 0 CC1(C)OC(CO[P+](*)(O)Cl)CO1 Chemical compound CC1(C)OC(CO[P+](*)(O)Cl)CO1 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 230000020176 deacylation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- XSQLMTVONUZXLD-UHFFFAOYSA-N CC1(C)OC(COP2(OCCO2)=O)CO1 Chemical compound CC1(C)OC(COP2(OCCO2)=O)CO1 XSQLMTVONUZXLD-UHFFFAOYSA-N 0.000 description 1
- NIHIZNMHNQIOER-UHFFFAOYSA-N C[N+](C)(C)CCOP(OC)(OCC(CO)O)=O Chemical compound C[N+](C)(C)CCOP(OC)(OCC(CO)O)=O NIHIZNMHNQIOER-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- SBMUNILHNJLMBF-UHFFFAOYSA-N O=P1(OCCO1)Cl Chemical compound O=P1(OCCO1)Cl SBMUNILHNJLMBF-UHFFFAOYSA-N 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- YLNSNVGRSIOCEU-ZCFIWIBFSA-N [(2r)-oxiran-2-yl]methyl butanoate Chemical compound CCCC(=O)OC[C@H]1CO1 YLNSNVGRSIOCEU-ZCFIWIBFSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- JGULOZKZZMBGFX-UHFFFAOYSA-L calcium;2-(trimethylazaniumyl)ethyl phosphate;chloride;tetrahydrate Chemical compound O.O.O.O.[Cl-].[Ca+2].C[N+](C)(C)CCOP([O-])([O-])=O JGULOZKZZMBGFX-UHFFFAOYSA-L 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-M choline phosphate(1-) Chemical compound C[N+](C)(C)CCOP([O-])([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-M 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- YLNSNVGRSIOCEU-UHFFFAOYSA-N oxiran-2-ylmethyl butanoate Chemical compound CCCC(=O)OCC1CO1 YLNSNVGRSIOCEU-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (10)
- 하기 화학식 2로 표시되는 콜린포스페이트와 하기 화학식 3으로 표시되는 라세믹 및 광학적으로 순도가 높은 (S) 또는 (R)-글리시돌 및 그의 유도체를 수용액 조건 하에서 고리열림 반응을 통하여 원팟(One-pot)반응으로 하기 화학식 1로 표시되는 것을 특징으로 하는 라세믹 및 광학적으로 활성이 있는 D 또는 L-α-글리세로포스포릴 콜린 및 그의 유도체를 제조하는 방법.[화학식 2][화학식 3][화학식 1](상기 화학식 1과 3에서 *는 키랄 센터를 의미하며 라세믹 및 광학 이성질체를 나타내고, R은 수소원자, 벤질기, 벤조일기, 메실기, 트리틸기, 토실기, 노실기 또는 탄소원자수가 2~30개를 갖는 아실기를 의미한다.)
- 제 1항에 있어서,상기 고리열림 반응에서 반응온도가 10에서 60℃에서 상기 화학식 1로 표시되는 것을 특징으로 하는 라세믹 및 광학적으로 활성이 있는 D 또는 L-α-글리세로포스포릴 콜린 및 그의 유도체를 제조하는 방법.
- 제 1항에 있어서,상기 고리열림 반응에서 반응 pH를 4에서 9로 수행하여 상기 화학식 1로 표시되는 것을 특징으로 하는 라세믹 및 광학적으로 활성이 있는 D 또는 L-α-글리세로포스포릴 콜린 및 그의 유도체를 제조하는 방법.
- 제 1항에 있어서,상기 고리열림 반응을 수용액상에서도 반응에 활성을 증가시켜주는 무기염기 또는 루이스 에시드를 이용하여 수용액 조건 하에서 반응을 수행하여 상기 화학식 1로 표시되는 것을 특징으로 하는 라세믹 및 광학적으로 활성이 있는 D 또는 L-α-글리세로포스포릴 콜린 및 그의 유도체를 제조하는 방법.
- 제 4항에 있어서,상기 고리열림 반응에서 무기염기를 사용하여 반응을 수행할 경우 수산화나트륨, 수산화칼륨, 수산화칼슘, 수산화마그네슘, 수산화바륨, 소듐카보네이트, 소듐바이카보네이트, 포타슘카보네이트, 포타슘바이카보네이트 중의 어느 하나를 선택하여 사용하는 것을 특징으로 하는 라세믹 및 광학적으로 활성이 있는 D 또는 L-α-글리세로포스포릴 콜린 및 그의 유도체를 제조하는 방법.
- 제 4항에 있어서,상기 고리열림 반응에서 루이스 에시드를 사용하여 반응을 수행할 경우 CuI, CuSO4, CuOTf2, SnSO4, AgPF6, AgBH4, Ag2SO4, BF3/Et2O, CsF, ZnOTf2 중의 어느 하나를 선택하여 사용하는 것을 특징으로 하는 라세믹 및 광학적으로 활성이 있는 D 또는 L-α-글리세로포스포릴 콜린 및 그의 유도체를 제조하는 방법.
- 제 4항에 있어서,상기 고리열림 반응에서 물 단독 용매 하에서 수행하거나 또는 필요에 따라 극성 유기용매를 소량첨가 하여 혼합 용매 하에서 반응을 수행하는 것을 특징으로 하는 라세믹 및 광학적으로 활성이 있는 D 또는 L-α-글리세로포스포릴 콜린 및 그의 유도체를 제조하는 방법.
- 제 7항에 있어서,물과 함께 사용될 수 있는 용매로는 N, N-디메틸포름아미드, N, N-디메틸아세트아미드, 디메틸설폭사이드, 아세톤, 아세토나이트릴 중의 어느 하나를 선택하여 사용하는 것을 특징으로 하는 라세믹 및 광학적으로 활성이 있는 D 또는 L-α-글리세로포스포릴 콜린 및 그의 유도체를 제조하는 방법.
- 제 1항에 있어서,상기 화학식 1로 표시되는 라세믹 및 광학적으로 활성이 있는 D 또는 L-α-글리세로포스포릴 콜린 및 그의 유도체를 최종적으로 제조하는 과정에서 추출용매로 사용되는 용매가 저급 알코올인 탄소원자수가 1에서 5개인 알코올류를 선택하여 사용하는 것을 특징으로 하는 라세믹 및 광학적으로 활성이 있는 D 또는 L-α-글리세로포스포릴 콜린 및 그의 유도체를 제조하는 방법.
- 제 4항에 있어서,반응온도가 10에서 60℃이고 반응 pH는 4에서 9인 상기 화학식 1로 표시되는 라세믹 및 광학적으로 활성이 있는 D 또는 L-α-글리세로포스포릴 콜린 및 그의 유도체를 제조하는 것을 특징으로 하는 라세믹 및 광학적으로 활성이 있는 D 또는 L-α-글리세로포스포릴 콜린 및 그의 유도체를 제조하는 방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080034490A KR100951108B1 (ko) | 2008-04-15 | 2008-04-15 | 라세믹 또는 광학적으로 활성이 있는 α-글리세로포스포릴콜린 및 그 유도체의 제조방법 |
PCT/KR2009/001894 WO2009128631A2 (ko) | 2008-04-15 | 2009-04-14 | 라세믹 또는 광학적으로 활성이 있는 α-글리세로포스포릴 콜린 및 그의 유도체의 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080034490A KR100951108B1 (ko) | 2008-04-15 | 2008-04-15 | 라세믹 또는 광학적으로 활성이 있는 α-글리세로포스포릴콜린 및 그 유도체의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090109172A KR20090109172A (ko) | 2009-10-20 |
KR100951108B1 true KR100951108B1 (ko) | 2010-04-07 |
Family
ID=41199557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080034490A KR100951108B1 (ko) | 2008-04-15 | 2008-04-15 | 라세믹 또는 광학적으로 활성이 있는 α-글리세로포스포릴콜린 및 그 유도체의 제조방법 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100951108B1 (ko) |
WO (1) | WO2009128631A2 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101330814B1 (ko) * | 2009-12-10 | 2013-11-15 | 주식회사 한서켐 | 콜린 알포세레이트의 제조방법 |
KR101233138B1 (ko) * | 2012-11-06 | 2013-02-22 | 주식회사 한서켐 | L-α-글리세릴 포스포릴 콜린의 제조방법 |
CN103304594B (zh) * | 2013-06-18 | 2015-07-08 | 上海科利生物医药有限公司 | 一种L-α-甘油磷酸胆碱的制备方法 |
KR20230023339A (ko) | 2021-08-10 | 2023-02-17 | 스마트바이오팜 주식회사 | 연속흐름공정을 이용하여 콜린알포세레이트를 제조하는 방법 |
CN114478622A (zh) * | 2022-03-17 | 2022-05-13 | 沈阳金久奇科技有限公司 | 一种磷脂酰胆碱的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4610979A (en) | 1983-03-05 | 1986-09-09 | A. Nattermann & Cie Gmbh | O-acyl-alkanediol-phospholipids and processes for the treatment of asthma |
EP0486100A1 (en) | 1990-11-15 | 1992-05-20 | MAGIS FARMACEUTICI S.p.A. | Process for preparing alpha-glycerophosphorylcholine |
KR19990064281A (ko) * | 1995-10-16 | 1999-07-26 | 존 바드웰 | 중합성 포스포디에스테르의 합성방법 |
KR20070119176A (ko) * | 2006-06-14 | 2007-12-20 | 주식회사 대웅제약 | L-α-글리세로포스포릴 콜린의 제조방법 |
-
2008
- 2008-04-15 KR KR1020080034490A patent/KR100951108B1/ko active IP Right Grant
-
2009
- 2009-04-14 WO PCT/KR2009/001894 patent/WO2009128631A2/ko active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4610979A (en) | 1983-03-05 | 1986-09-09 | A. Nattermann & Cie Gmbh | O-acyl-alkanediol-phospholipids and processes for the treatment of asthma |
EP0486100A1 (en) | 1990-11-15 | 1992-05-20 | MAGIS FARMACEUTICI S.p.A. | Process for preparing alpha-glycerophosphorylcholine |
KR19990064281A (ko) * | 1995-10-16 | 1999-07-26 | 존 바드웰 | 중합성 포스포디에스테르의 합성방법 |
KR20070119176A (ko) * | 2006-06-14 | 2007-12-20 | 주식회사 대웅제약 | L-α-글리세로포스포릴 콜린의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
WO2009128631A2 (ko) | 2009-10-22 |
WO2009128631A3 (ko) | 2010-01-21 |
KR20090109172A (ko) | 2009-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100966627B1 (ko) | L-α-글리세로포스포릴 콜린의 제조방법 | |
EP3106465B1 (en) | Method for preparing racemic or optically active glycerophosphoryl choline | |
CA2485597C (en) | Process for preparation of cyclic prodrugs of pmea and pmpa | |
KR100951108B1 (ko) | 라세믹 또는 광학적으로 활성이 있는 α-글리세로포스포릴콜린 및 그 유도체의 제조방법 | |
PT2046726E (pt) | Preparação da (2r,3r)-3-(3-metoxifenil)-n,n,2- trimetilpentanamina | |
JP5044965B2 (ja) | α−グリセロホスホリルコリン結晶の製造方法 | |
CA2812178C (en) | Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof | |
KR101179470B1 (ko) | 라세믹체, D체 또는 L-α-글리세릴 포스포릴콜린의 신규한 제조방법 | |
EP0262227B1 (en) | Process for the preparation of myoinositol derivatives | |
JPH041759B2 (ko) | ||
RU2326885C1 (ru) | Способ получения диизопропил ((1-(гидроксиметил)-циклопропил)окси) метилфосфоната | |
JP4201916B2 (ja) | 光学活性な1,2−ビス(ジアルキルホスフィノ)ベンゼン誘導体及びその製造方法、並びに該化合物を配位子とするロジウム金属錯体 | |
KR100926844B1 (ko) | 스핑고신의 합성을 위한 제조방법 | |
KR101023455B1 (ko) | 라세믹 또는 광학적으로 활성이 있는 α―글리세로포스포릴콜린의 제조방법 | |
KR101330814B1 (ko) | 콜린 알포세레이트의 제조방법 | |
Gryshkun et al. | Enantioselective reduction of ketophosphonates using adducts of chiral natural acids with sodium borohydride | |
KR20100094004A (ko) | 라세믹 또는 광학적으로 활성이 있는 α―글리세로포스포릴콜린의 제조방법 | |
KR101019728B1 (ko) | 라세믹 또는 광학적으로 활성이 있는 α―포스파티딜콜린 유도체의 제조방법 | |
JP3901321B2 (ja) | リボフラビン−5’−リン酸またはそのナトリウム塩の製造法 | |
Nesterov et al. | Enantioselective reduction of ketophosphonates using chiral acid adducts with sodium borohydride | |
JPS5940839B2 (ja) | 混合酸型1,2−ジアシル−3−グリセリルホスホリルコリン類の製法 | |
KR101195631B1 (ko) | 9-[2-(포스포노메톡시)에틸]아데닌의 개선된 제조방법 | |
KR101247653B1 (ko) | 아데포비어 디피복실 제조방법 | |
RU2486191C1 (ru) | Способ получения 1,2-бис(гидроксиметил)-о-карборана | |
JP7303618B2 (ja) | スフィンゴリン脂質前駆体及びその製造方法、並びに、スフィンゴリン脂質の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130618 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141229 Year of fee payment: 5 |
|
R401 | Registration of restoration | ||
FPAY | Annual fee payment |
Payment date: 20151228 Year of fee payment: 6 |
|
R401 | Registration of restoration | ||
FPAY | Annual fee payment |
Payment date: 20160427 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170619 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190321 Year of fee payment: 10 |
|
R401 | Registration of restoration | ||
R401 | Registration of restoration |